Clinical trials: Carcinoma of Lung
Lung Cancer, Atrial Fibrillation
Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection
Lung resections for pulmonary malignancies offer the best chance of survival for patients, but these procedures carry a significant burden of post-operative morbidity and mortality.
- Conditions
- Lung Cancer, Atrial Fibrillation, Stroke
- Trial name
- Lung-AF (NCT02547168)
- Testing
- iRhythm ZIO XT patch
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- McMaster University
Breast Cancer, Lung Cancer
The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients
The purpose of this study is to evaluate the effectiveness and feasibility of the Screening Inventory of Psychosocial Problems (SIPP) in consultation settings with respect to early recognition and treatment of psychosocial…
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer, Bladder Cancer
- Trial name
- NCT00859768
- Testing
- Questionnaire administration
- Where
- Netherlands
- Volunteers
- 568 people
- Sponsor
- Netherlands Open University
Non-Small Cell Lung Cancer
A Study of Prevalence of EGFR Mutations in Participants With NSCLC
This is a non-interventional, local, multicenter, cross-sectional study to determine the prevalence of epidermal growth factor receptor (EGFR) mutations in participants diagnosed with non-squamous non-small cell lung cancer…
- Trial name
- NCT02695849
- Where
- 2 sites in Jordan
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers.
- Trial name
- CHIARA (NCT01562015)
- Testing
- Ganetespib
- Where
- 5 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Synta Pharmaceuticals Corp.
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Lung Neoplasms
Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer
This study is designed to apply various scans such as functional imaging, Fluorodeoxyglucose_Positron Emission Tomography (FDG-PET), 62Cu-ETS (Copper) PET, Ventilation/Perfusion Single Photon Emission Computerized Tomography (V/Q…
- Trial name
- NCT02117440
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab…
- Trial name
- PACIFIC-9 (NCT05221840)
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 202 sites in United States, Australia and 18 more
- Volunteers
- 1,051 people
- Sponsor
- AstraZeneca
Lung Cancer
Objective and Subjective Outcomes of an Electronic Chest Drainage System
This study is designed to compare the Thopaz chest tube drainage system to the traditional collection chamber system. The Thopaz system is already in clinical use in the United States and throughout the world.
- Trial name
- NCT01747889
- Testing
- electronic chest drainage system
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Ospedali Riuniti Ancona
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT06282874
- Testing
- Lorlatinib
- Where
- 3 sites in China
- Volunteers
- 41 people
- Sponsor
- Guangdong Association of Clinical Trials
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
This phase II trial studies how well fludeoxyglucose F 18 (FDG)-labeled positron emission tomography (PET) scan works in planning chemotherapy in treating patients with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Conditions
- Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00564733
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Washington
Lung Carcinoma, Tobacco Use Disorder
Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
This randomized phase II trial studies the safety and effects of acetylsalicylic acid (aspirin) taken continuously or intermittently on gene expression in the nasal tissue of current smokers.
- Trial name
- NCT02123849
- Testing
- Aspirin, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with NSCLC who have progressed on or after treatment with PD-1/PD-L1 inhibitors.
- Trial name
- NCT03169738
- Testing
- avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Non Small Cell Lung Cancer, Cancer of the Head and Neck
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
The purpose of this study is to provide ZD1839 for those patients with locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV) or recurrent and/or metastatic squamous cell head and neck cancer…
- Trial name
- NCT00684385
- Testing
- ZD1839
- Where
- 34 sites in Germany, Hungary and 2 more
- Sponsor
- AstraZeneca
Non-small-cell Lung Cancer
A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer
This study will evaluate the efficacy and safety of QL1706 when given in combination with bevacizumab, paclitaxel or pemetrexed, and carboplatin in patients with Stage IIIB/C and Stage IV Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT05329025
- Testing
- QL1706
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
This study explores how adjuvant therapy affects survival in completely resected high-risk stage IA-IB NSCLC patients with different driver gene mutations.
- Trial name
- UPLIFT (NCT06955325)
- Testing
- Icotinib, Rezivertinib, Ensartinib
- Volunteers
- 270 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
CK-101 is a novel, potent, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Adenocarcinoma
- Trial name
- NCT02926768
- Testing
- CK-101
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 136 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Smoking Reduction, Tobacco Use
Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment
This pragmatic trial will evaluate the value of routinely providing proactive smoking cessation support to current smokers as a part of participating in lung cancer screening within Veterans Health Administration.
- Conditions
- Smoking Reduction, Tobacco Use, Tobacco Smoking, Tomography
- Trial name
- PROACT (NCT03612804)
- Testing
- Unsigned note to provider about cessation medication prescription, Proactive Telephone Counseling from VA Quitline
- Where
- 3 sites in United States
- Volunteers
- 944 people
- Sponsor
- VA Office of Research and Development
Kidney Cancer, Bladder Cancer
A Study of a Side Effects and Resource Navigation Program for People With Cancer
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care.
- Conditions
- Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT07646847
- Testing
- Immunotherapy CARE Program
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
Clinical Outcomes and Quality Of Life After Minimally Invasive Segmentectomy Versus Lobectomy for Lung Cancer
The goal is to compare patient reported outcomes, such as dyspnea, physical functioning and quality of life, between minimally invasive segmentectomy and lobectomy for stage I NSCLC during the first year after surgery.
- Trial name
- NCT07477158
- Where
- Spain
- Volunteers
- 180 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Non-Small Cell Lung Cancer (NSCLC)
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
This open-label, randomized, multinational, non-comparative, phase IIIb trial with 2 parallel groups will screen about 1400 subjects with stage IIIB non-small cell lung cancer (NSCLC) with pleural effusion or stage IV NSCLC.
- Trial name
- NEXT (NCT00820755)
- Testing
- Cetuximab plus Platinum-based Doublet Chemotherapy, Cetuximab 500 mg/m^2, Cetuximab 250 mg/m^2
- Where
- Germany
- Volunteers
- 583 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.